What is Sarcomatoid Mesothelioma?
Sarcomatoid mesothelioma is the most aggressive form of mesothelioma. It accounts for 10 to 20 percent of all mesothelioma cases and carries the worst prognosis of any histological subtype. Patients and families deserve honest, accurate information about what this diagnosis means — not false reassurance, and not information that leaves them without a clear picture of their options.
The picture has changed. Until recently, sarcomatoid mesothelioma had almost nothing to offer beyond platinum-pemetrexed chemotherapy, which produces modest benefit. The CheckMate 743 trial changed that. In the non-epithelioid subgroup — which is predominantly sarcomatoid and biphasic patients — dual checkpoint immunotherapy produced a median survival of 16.5 months compared to 8.8 months with chemotherapy. That is one of the largest treatment effects ever observed in this subtype, and it has transformed first-line treatment recommendations.
The urgency of a sarcomatoid diagnosis is real. Acting quickly — medically and legally — is essential.
Learn about all mesothelioma cell types and how they affect treatment.
What Sarcomatoid Cells Are
Sarcomatoid mesothelioma cells are spindle-shaped, elongated, and disorganized. Unlike epithelioid cells, which form recognizable architectural structures, sarcomatoid cells grow in fascicles or sheets without clear cohesion. They are poorly differentiated — they retain little resemblance to the original mesothelial cell — which is why they grow faster, invade more readily, and respond less well to most systemic treatments.
The 2021 WHO classification formalized an important change: transitional mesothelioma, a cell type with features intermediate between epithelioid and sarcomatoid, is now classified as sarcomatoid. Many cases previously labeled "transitional" are now appropriately classified as sarcomatoid, and their clinical behavior is consistent with that reclassification.
Sarcomatoid Variants
Within the sarcomatoid category, two variants carry distinct clinical significance.
Lymphohistiocytoid mesothelioma is a sarcomatoid variant characterized by abundant inflammatory cell infiltrates. It carries a relatively better prognosis within the sarcomatoid subtype and is notable for high PD-L1 expression — which may explain why it tends to respond well to checkpoint immunotherapy. Accurate identification of the lymphohistiocytoid variant is clinically important because it affects both prognosis and treatment strategy.
Desmoplastic mesothelioma is defined by dense, collagen-rich stroma comprising at least 50 percent of the tumor volume. This variant is among the most difficult to diagnose correctly because the paucicellular, fibrous appearance can closely mimic benign fibrous pleurisy. The key diagnostic marker is cytokeratin expression (AE1/AE3), which is retained in desmoplastic mesothelioma even when other markers are weak. BAP1 loss, MTAP loss, and CDKN2A deletion by FISH provide additional molecular confirmation. Prognosis for desmoplastic mesothelioma is generally under one year from symptom onset. Metastatic spread to the liver, contralateral lung, adrenal glands, kidneys, and bone is more common in desmoplastic disease than in other sarcomatoid variants.
How Doctors Diagnose Sarcomatoid Mesothelioma
Accurate diagnosis of sarcomatoid mesothelioma is technically demanding and carries a higher rate of misdiagnosis than epithelioid disease. The consequences of misclassification are significant: a sarcomatoid mesothelioma misidentified as a true sarcoma may receive the wrong chemotherapy regimen. A desmoplastic variant misidentified as fibrous pleurisy may receive no treatment at all.
Tissue requirements. Thoracoscopic biopsy generally provides the best specimens for sarcomatoid diagnosis. The tissue requirements are particularly demanding because superficial biopsies may capture only the bland, fibrotic surface of a tumor while missing the deeper areas of cellular atypia and invasion that confirm malignancy. Full-thickness tissue samples that include the interface between the tumor and underlying chest wall or lung tissue are ideal.
Immunohistochemistry. IHC follows a different logic for sarcomatoid mesothelioma than for epithelioid disease. The classic mesothelioma markers — calretinin, WT-1, and D2-40 — are less reliably expressed in sarcomatoid tumors. Calretinin may be negative or only focally positive. Cytokeratin expression, particularly with broad-spectrum keratins (AE1/AE3), becomes the most critical positive marker because it distinguishes sarcomatoid mesothelioma from true sarcomas and other mesenchymal tumors that are cytokeratin-negative. Negative markers — S-100, desmin, and CD34 — help exclude sarcomas, nerve sheath tumors, and solitary fibrous tumors from the differential diagnosis.
Molecular markers. Loss of BAP1 expression, loss of MTAP expression, and homozygous deletion of CDKN2A detected by FISH all support a mesothelioma diagnosis. CDKN2A deletions are most frequent in the sarcomatoid subtype, making FISH testing for this alteration particularly relevant when sarcomatoid mesothelioma is in the differential.
TSDUT differential. The 2021 WHO classification introduced thoracic SMARCA4-deficient undifferentiated tumor (TSDUT) as an important differential diagnosis for sarcomatoid mesothelioma. This recently recognized tumor can closely mimic sarcomatoid mesothelioma both clinically and histologically but carries a distinct molecular profile and different treatment implications.
Expert pathology review is not optional for suspected sarcomatoid mesothelioma — it is essential. A second opinion from a mesothelioma-specialized pathologist is appropriate for every sarcomatoid diagnosis.
Staging
Mesothelioma staging uses the TNM system, with the 9th edition (2024) as the current standard. The revised staging groups run from Stage I (T1N0) through Stage IV (any M1).
For sarcomatoid mesothelioma, staging has a fundamentally different clinical significance than it does for epithelioid disease. In the SEER population-based analysis of 1,183 mesothelioma patients, increasing stage was not associated with statistically significant differences in survival within the sarcomatoid subtype. More strikingly, stage did not predict surgical benefit: patients with early-stage (Stage I or II) sarcomatoid disease who underwent surgery had a median survival of just 4 months — identical to early-stage sarcomatoid patients who did not undergo surgery, and far worse than the survival of epithelioid patients at any stage.
A patient with Stage III epithelioid mesothelioma has a longer expected survival than a patient with Stage I sarcomatoid disease. This finding reinforces why accurate histological identification must happen before treatment planning, not after.
Staging remains important for clinical trial eligibility, treatment planning, and ruling out metastatic disease that would eliminate certain options. But in sarcomatoid mesothelioma, the biology of the tumor overwhelms the prognostic significance of how far the disease has spread.
Treatment Options
Treatment for sarcomatoid mesothelioma operates within narrower margins than for epithelioid disease. The aggressive biology limits the effectiveness of many standard approaches, and the evidence base consistently shows that treatments benefiting epithelioid patients often fail to produce measurable survival improvements in sarcomatoid patients.
Surgery. Current guidelines from NCCN, ESMO, and the ERS/ESTS/EACTS uniformly recommend against radical surgery for sarcomatoid mesothelioma. The SEER data provide the population-level evidence: in multivariate analysis, cancer-directed surgery was not associated with improved survival in the sarcomatoid group (hazard ratio 0.79, P = 0.18). Even when the analysis was limited to likely curative-intent procedures, surgery showed no statistically significant benefit. Yet 26 percent of sarcomatoid patients in the SEER cohort still received cancer-directed surgery — suggesting that some patients continue to undergo operations unlikely to help them.
Surgery for sarcomatoid mesothelioma is generally limited to palliative procedures aimed at relieving symptoms such as pleural effusion or pain.
Chemotherapy. Platinum-pemetrexed combination chemotherapy remains the standard first-line systemic treatment for patients who are not candidates for immunotherapy. Response rates are generally lower in sarcomatoid disease than in epithelioid, and the survival benefit is modest. However, chemotherapy remains an option for patients who cannot tolerate or do not respond to immunotherapy.
Immunotherapy. The CheckMate 743 trial transformed the treatment landscape for sarcomatoid mesothelioma. While the overall trial results showed median survival of 18.1 months for immunotherapy versus 14.1 months for chemotherapy, the non-epithelioid subgroup results were remarkable: immunotherapy produced a median survival of 16.5 months compared to just 8.8 months with chemotherapy — a hazard ratio of 0.46, meaning immunotherapy cut the risk of death by more than half. This is one of the largest treatment effects ever observed in sarcomatoid mesothelioma and has fundamentally changed first-line treatment recommendations for this subtype.
The IND.227 trial tested pembrolizumab combined with platinum-pemetrexed chemotherapy and showed improvement in overall survival (hazard ratio 0.79). The benefit was larger in the non-epithelioid subgroup on exploratory analysis.
The biological explanation for this counterintuitive finding — that the most treatment-resistant subtype responds best to immunotherapy — likely relates to the molecular characteristics of sarcomatoid tumors. Sarcomatoid mesotheliomas frequently express PD-L1, display increased lymphocytic inflammation, and have a tumor microenvironment enriched with T-cells and monocytes. These are precisely the features that predict response to immune checkpoint inhibitors. An emerging inflammatory signature score based on RNA expression of CD-8A, PD-L1, LAG-3, and STAT1 may serve as a predictive biomarker for identifying which sarcomatoid patients will benefit most from dual checkpoint inhibitor therapy.
For sarcomatoid mesothelioma patients, the immunotherapy data represent a genuine step forward. For the first time, there is a first-line treatment approach where sarcomatoid histology may actually be an advantage rather than a liability.
Prognosis and Survival
Sarcomatoid mesothelioma carries the poorest prognosis of any mesothelioma subtype. Patients and families deserve accurate information about expected outcomes to make informed decisions about treatment, legal action, and how they choose to spend their time.
In SEER population-based data, the overall median survival for sarcomatoid mesothelioma was 4 months. With cancer-directed surgery, median survival was 4 months; without surgery, it was 3 months. Among surgical patients, sarcomatoid histology carried a hazard ratio of 2.68 compared to epithelioid — meaning the risk of death was nearly three times higher, after adjusting for age, stage, and other variables.
These figures predate the immunotherapy era. The CheckMate 743 data showing median survival of 16.5 months for non-epithelioid patients treated with nivolumab plus ipilimumab represent a substantial improvement over historical chemotherapy outcomes of 8.8 months. However, these trial populations were selected for adequate performance status and may not reflect outcomes across the full range of sarcomatoid patients seen in clinical practice.
Within the sarcomatoid subtype, the factors that most influence individual prognosis are performance status (patients who are physically functional tolerate treatment better and live longer), access to immunotherapy (which has become the most important treatment variable for this subtype), and the presence of lymphohistiocytoid features (associated with better outcomes within sarcomatoid disease). The desmoplastic variant carries a prognosis consistent with sarcomatoid disease generally — mean survival under one year from symptom onset.
Long-term survival with sarcomatoid mesothelioma is exceedingly rare. In the SEER data, five-year survival for sarcomatoid patients who underwent surgery was 0 percent across all stages. This reality underscores the urgency — both medical and legal — that accompanies a sarcomatoid diagnosis.
Asbestos and Sarcomatoid Mesothelioma
Sarcomatoid mesothelioma is caused almost exclusively by asbestos exposure. The latency period between initial exposure and diagnosis spans 20 to 50 years, and the mechanisms are identical to those that produce epithelioid disease: inhaled asbestos fibers lodge in pleural tissue, cause decades of chronic inflammation and DNA damage, and ultimately trigger malignant transformation of the mesothelial cells.
What distinguishes sarcomatoid mesothelioma is not the cause but the cellular response. The same asbestos fibers that produce organized, epithelioid-pattern tumors in some patients produce disorganized, spindle-cell tumors in others. Current research suggests that the specific genetic alterations triggered by asbestos fiber damage — particularly patterns involving CDKN2A deletions and BAP1 mutations — may influence which histological subtype ultimately develops, though the precise mechanisms remain under investigation.
All six regulated types of asbestos are capable of causing sarcomatoid mesothelioma. The industries and occupations with the highest exposure risk are: shipbuilding, power generation, construction trades, petrochemical refining, automotive manufacturing, steel production, and military service. Secondary exposure, where family members inhale fibers carried home on a worker's clothing or skin, is another established pathway.
Learn more about asbestos exposure by occupation. | Learn more about secondary take-home exposure.
Legal Rights and Compensation
A sarcomatoid mesothelioma diagnosis creates urgent legal considerations that differ from those facing epithelioid patients. The aggressive nature and shorter expected survival mean that time is the scarcest resource, and legal action must begin quickly to preserve the patient's rights and maximize the compensation available to them and their family.
Every compensation pathway available to epithelioid patients is equally available to sarcomatoid patients. Asbestos trust fund claims, personal injury lawsuits, wrongful death claims, and VA disability benefits all depend on documented asbestos exposure and a confirmed mesothelioma diagnosis, not on which histological subtype is present. The sarcomatoid subtype does not reduce eligibility or claim value. In many cases, the urgency and severity of sarcomatoid disease can support higher compensation, because the rapid decline in quality of life, the limited treatment options, and the compressed timeline of suffering are all factors that courts and trust fund administrators consider.
The practical challenge is speed. With a median survival measured in months, sarcomatoid patients may not survive the length of a typical lawsuit. Experienced mesothelioma firms understand this and use expedited filing procedures, priority scheduling motions, and early deposition strategies to ensure that the patient's testimony and exposure history are preserved. Trust fund claims, which do not require litigation, can often be filed and resolved more quickly.
Our firm has recovered more than $400 million for asbestos victims and their families. We maintain a proprietary database of over 200,000 verified asbestos exposure sites across the United States, which allows us to identify exposure sources rapidly. That capability is especially critical for sarcomatoid patients who cannot afford months of investigation.
Explore all your legal options. | Learn about VA benefits for veterans. | Learn how we build cases other firms can't.
Take the Next Step
If you or a family member has been diagnosed with sarcomatoid mesothelioma, do not wait. Call 833-4-ASBESTOS for a free, confidential consultation, or visit our legal options page to learn more about the compensation pathways available to you.
The consultation is free. There's no obligation. You pay nothing unless we recover compensation for you.
Call 833-4-ASBESTOS (833-427-2378) or schedule your free consultation online.
References
Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO Classification of Tumors of the Pleura: advances since the 2015 classification. J Thorac Oncol. 2022;17(5):608-622. doi:10.1016/j.jtho.2021.12.014
Meyerhoff RR, Yang CJ, Speicher PJ, et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196(1):23-32. doi:10.1016/j.jss.2015.01.043
Cardillo G, Waller D, Tenconi S, Di Noia V, Ricciardi S. Malignant Pleural Mesothelioma: A 2025 Update. J Clin Med. 2025;14(3):1004. doi:10.3390/jcm14031004
Nowak AK, Giroux DJ, Eisele M, et al. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024;19(9):1339-1351. doi:10.1016/j.jtho.2024.05.020
Lim E, Waller D, Lau K, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med. 2024;12(6):457-466. doi:10.1016/S2213-2600(24)00028-2
Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644. doi:10.1200/JCO.2003.11.136
Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. doi:10.1016/S0140-6736(20)32714-8
Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488-499. doi:10.1016/j.annonc.2022.01.074
Chu Q, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402(10419):2295-2306. doi:10.1016/S0140-6736(23)01148-4
Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised phase 3 trial. Lancet Oncol. 2021;22(11):1530-1540. doi:10.1016/S1470-2045(21)00471-X